Journal article
CXCL5 knockdown attenuated gemcitabine resistance of pancreatic cancer through regulation of cancer cells and tumour stroma
Nien-Hung Lee, Yi Ma, Ching-Seng Ang, Chelsea Dumesny, Nhi Huynh, Yang Yang, Kai Wang, Mehrdad Nikfarjam, Hong He
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH | E-CENTURY PUBLISHING CORP | Published : 2023
Abstract
Chemoresistance is one of the major causes to the poor prognosis of pancreatic cancer (PC). Gemcitabine alone and gemcitabine-based therapies are mostly used for the treatment of PC. Gemcitabine resistance becomes the focus of chemotherapy. C-X-C motif chemokine 5 (CXCL5), a member of the C-X-C chemokine family, acts through C-X-C chemokine receptor type 2 (CXCR2). A high level of CXCL5 is associated with worse prognosis in PC patients and increased suppressive immune cell infiltration. Increased expression of CXCL5 is also found in gemcitabine-treated PC cells. To investigate the role of CXCL5 in PC response to gemcitabine, CXCL5 knockdown (KD) PC cells were generated and its effect on canc..
View full abstractGrants
Awarded by Melbourne Medical School Department of Surgery Seeding
Awarded by China Postdoctoral Council
Funding Acknowledgements
The authors would like to acknowledge the Australian Government Research Training Program Scholarship and Royal Australasian College of Surgeons (RACS) Foundation of Surgery Scholarship for supporting Yi Ma. Dr Hong He is supported by the Henry Baldwin Cancer Research Trust Fund. This work is supported by Austin Medical Research Foundation grants (AMRF, He & Nikfarjam) , Melbourne Medical School Department of Surgery Seeding Grants (Nikfarjam-2020, He -2021) , Pancare Foundation ( www.pancare.org.au) and Tour De Cure grants. Yang Yang is supported by China Postdoctoral Council (No. 20180028) and Pancare Foundation.